Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Bluetongue vaccine manufacturers urged to restart production
vet with cow
"Planning for adequate vaccine production and uptake is now essential" - NSA.

Strong possibility disease could hit the UK this summer

With the expected arrival of Bluetongue from France this summer, the National Sheep Association are urging vaccine manufacturers to restart production.

A recent report published by the Animal Plant and Health Agency showed there was an 80 per cent chance of the bluetongue virus serotype 8 (BTV8) hitting UK shores later this year.

In a statement released last Wednesday (30 March), the NSA say that they are working hard to keep the need for an agreed disease control strategy ‘at the top of the agenda.’

According to the NSA, the French Government currently owns all existing vaccine for BTV8 and has made it compulsory for any stock exiting the restriction zone in France to comply with pre-movement vaccination stipulations. There is currently no vaccine available in the UK.

“The NSA position, which is shared by the Sheep Veterinary Society, is that we must do all we can to keep the UK clear of the virus and not allow it to become endemic if it does arrive,"
said NSA chief executive Phil Stocker.

“We should treat any opinion that this is a ‘low impact’ disease with extreme caution, as while there may be some residual immunity in France, we do not believe that is the case here. The UK remains highly vulnerable, with a potential BTV8 outbreak posing real welfare and production problems.

“Many NSA members tell me that, if a vaccine was available at a reasonable cost, they would choose to use it. Whether that would get usage to a level that would protect the national flock is questionable, but that is where we are at the moment and the most important challenge is to get adequate approved and inactive vaccine stocks available at a price that encourages uptake.”

So far the NSA understands the majority of confirmed cases in France have been picked up through surveillance rather than clinical signs. Experts suggest that circulation is presently limited due to unstable weather conditions and/or a degree of residual immunity being present.

“Given that the UK is an island nation and we have the potential to protect ourselves through vaccination in advance of any spread to our shores, planning for adequate vaccine production and uptake is now essential,” continued Mr. Stocker.

“I urge producers in potentially vulnerable areas to seriously think about how an outbreak of bluetongue could impact on their own stock and their ability to move stock, and to consider committing to a vaccination programme. I also urge vaccine manufacturers to step up their communication with the UK livestock industry and to start preparing the way for manufacture.” 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.